Kang Peng Technology announced that in the first half of 2026, it achieved operating income of 311 million yuan, a year-on-year decrease of 28.72%; net loss attributable to shareholders of listed companies was 41 million yuan, which changed from profit to loss over the previous year; net loss of 47 million yuan after deducting non-recurring profit and loss. The change in performance was mainly due to a marked decline in the CDMO business, with a significant year-on-year decline in the share of overseas business. The gross margin of main business revenue decreased by 14.69 percentage points year-on-year due to changes in sales product structure. In the first half of 2026, the company terminated some fund-raising projects and postponed the medical peptide manufacturing capacity improvement project until June 2027; independent director Wang Yue left office and elected Tang Yi as the new independent director.

Kang Peng Technology announced that in the first half of 2026, it achieved operating income of 311 million yuan, a year-on-year decrease of 28.72%; net loss attributable to shareholders of listed companies was 41 million yuan, which changed from profit to loss over the previous year; net loss of 47 million yuan after deducting non-recurring profit and loss. The change in performance was mainly due to a marked decline in the CDMO business, with a significant year-on-year decline in the share of overseas business. The gross margin of main business revenue decreased by 14.69 percentage points year-on-year due to changes in sales product structure. In the first half of 2026, the company terminated some fund-raising projects and postponed the medical peptide manufacturing capacity improvement project until June 2027; independent director Wang Yue left office and elected Tang Yi as the new independent director.